Celeste Porsbjerg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Celeste Porsbjerg has a total of 798 co-authors. Here are the top co-authors by number of shared publications:
Vibeke Backer
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University , Copenhagen
31 shared publications- Vibeke Backer
Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark
24 shared publications Asger Sverrild
Respiratory Research Unit, Department of Respiratory and Infectious Disease, Bispebjerg University Hospital, Copenhagen, Denmark
13 shared publicationsV. Backer
Department of Respiratory Medicine L, Bispebjerg Hospital and University of Copenhagen, Copenhagen, Denmark
11 shared publications- Charlotte Suppli Ulrik
Department of Respiratory Medicine, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark
8 shared publications - Morten Hvidtfeldt
Respiratory Research Unit, Department of Respiratory and Infectious Diseases Bispebjerg University Hospital Copenhagen Denmark
8 shared publications
Latest Publications
- 10 December 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 291-293
Clustering of the Bronchial Epithelial Immune Response to Viral Stimulation in Patients With Asthma Identifies Clinically Recognisable Epithelial Exacerbation Response Profiles
Summary: Clustering of bronchial epithelial immune responses to a viral mimic identifies distinct immune response patterns. Induction of epithelial alarmins differs markedly, with only TSLP being associated with severe eosinophilic disease.
- 10 December 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (3) , 291-293
Clustering of the Bronchial Epithelial Immune Response to Viral Stimulation in Patients With Asthma Identifies Clinically Recognisable Epithelial Exacerbation Response Profiles
Summary: Clustering of bronchial epithelial immune responses to a viral mimic identifies distinct immune response patterns. Induction of epithelial alarmins differs markedly, with only TSLP being associated with severe eosinophilic disease.
- Open Access
- 28 October 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (2) , 241-252
Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial
Rationale: Chronic mucus hypersecretion contributes to airway obstruction in asthma. Objectives: To assess dupilumab efficacy by baseline mucus plug score. Methods: In VESTIGE (NCT04400318), adults with moderate-to-severe asthma, baseline blood eosinophils ≥300 cells/μL, and fractional exhaled nitric oxide (FeNO) ≥25 ppb received dupilumab 300 mg (n = 72) or placebo (n = 37) every 2 weeks for 24 weeks. Post hoc analyses included mucus plug score change from baseline, and patient proportion achieving FeNO <25 ppb, percent predicted FEV1, and FVC stratified by baseline mucus plug score (high/low defined by score ≥4 or 0-3.5, respectively, derived from high-resolution computed tomography scans). Measurements and Main Results: Fewer dupilumab-receiving patients had high mucus plug score at week 24 than at baseline (32.8% vs 67.2%); proportions remained similar in placebo-receiving patients (76.7% vs 73.3%). Dupilumab versus placebo recipients were more likely to achieve FeNO <25 ppb in high-/low-mucus-plug score subgroups (odds ratio, 6.64; P = .003/8.54; P = .024). Dupilumab versus placebo significantly increased pre-/post-bronchodilator percent predicted FEV1 (least squares mean difference [LSMD], 16.77 percentage points [95% CI, 9.81-23.73]; P <.0001 [pre] and 12.70 [95% CI, 3.87-21.52]; P = .0055 [post]) and pre-bronchodilator FVC (LSMD, 0.42 mL [95% CI, 0.17-0.66]; P = .001), and numerically improved post-bronchodilator FVC (LSMD, 0.30 mL [95% CI, 0.01-0.59]; P = .0399) in the high-mucus-plug score subgroup. Conclusions: Dupilumab reduced mucus plug scores and improved lung function in patients with moderate-to-severe asthma with high baseline mucus plug score, and increased the likelihood of achieving FeNO <25 ppb regardless of baseline mucus plug score.
- 28 October 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (2) , 241-252
Open AccessEffect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial
Rationale: Chronic mucus hypersecretion contributes to airway obstruction in asthma. Objectives: To assess dupilumab efficacy by baseline mucus plug score. Methods: In VESTIGE (NCT04400318), adults with moderate-to-severe asthma, baseline blood eosinophils ≥300 cells/μL, and fractional exhaled nitric oxide (FeNO) ≥25 ppb received dupilumab 300 mg (n = 72) or placebo (n = 37) every 2 weeks for 24 weeks. Post hoc analyses included mucus plug score change from baseline, and patient proportion achieving FeNO <25 ppb, percent predicted FEV1, and FVC stratified by baseline mucus plug score (high/low defined by score ≥4 or 0-3.5, respectively, derived from high-resolution computed tomography scans). Measurements and Main Results: Fewer dupilumab-receiving patients had high mucus plug score at week 24 than at baseline (32.8% vs 67.2%); proportions remained similar in placebo-receiving patients (76.7% vs 73.3%). Dupilumab versus placebo recipients were more likely to achieve FeNO <25 ppb in high-/low-mucus-plug score subgroups (odds ratio, 6.64; P = .003/8.54; P = .024). Dupilumab versus placebo significantly increased pre-/post-bronchodilator percent predicted FEV1 (least squares mean difference [LSMD], 16.77 percentage points [95% CI, 9.81-23.73]; P <.0001 [pre] and 12.70 [95% CI, 3.87-21.52]; P = .0055 [post]) and pre-bronchodilator FVC (LSMD, 0.42 mL [95% CI, 0.17-0.66]; P = .001), and numerically improved post-bronchodilator FVC (LSMD, 0.30 mL [95% CI, 0.01-0.59]; P = .0399) in the high-mucus-plug score subgroup. Conclusions: Dupilumab reduced mucus plug scores and improved lung function in patients with moderate-to-severe asthma with high baseline mucus plug score, and increased the likelihood of achieving FeNO <25 ppb regardless of baseline mucus plug score.
- Open Access
Long‐Term, Real‐World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma
Background: Respiratory allergies often begin in childhood and can progress over time, leading to increased disease burden. Allergen immunotherapy (AIT) is the only causal treatment for allergic respiratory diseases with disease‐modifying potential. While randomised trials support its efficacy in controlling allergic rhinitis (AR) and asthma symptoms, long‐term real‐world data in children remain limited. Methods: This paediatric study ( n = 11,036) was conducted within the pre‐defined framework of the REACT study, based on protocol‐specified objectives. Children (< 18 years) with physician‐diagnosed AR, with or without pre‐existing asthma, were included. AIT‐treated patients were matched 1:1 to non‐AIT controls. Effectiveness was assessed over 9 years by comparing AR and asthma medication prescriptions, using a public database covering all reimbursable AIT products. Relative differences were calculated across the full observation period. Results: AIT‐treated children (mean age 11.4 years; 62.1% male) exhibited greater reductions in AR medication use than controls (additional 9% reduction beyond 61% in controls). In children with asthma, AIT was associated with additional reductions in asthma medication use (−21% beyond −48% in controls), severe exacerbations (−21% beyond −36%), and new oral corticosteroid prescriptions (−33% beyond −41%). Age stratification revealed more pronounced AR medication reductions in younger children (0–11 years) than in adolescents (12–17 years). Conclusion: This large‐scale, real‐world study supports the long‐term effectiveness of AIT in children with AR, with or without asthma. The findings reflect improved disease control and suggest a disease‐modifying effect of AIT. Early intervention, particularly in younger children, may help mitigate the progression of allergic disease.
Open AccessLong‐Term, Real‐World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma
Background: Respiratory allergies often begin in childhood and can progress over time, leading to increased disease burden. Allergen immunotherapy (AIT) is the only causal treatment for allergic respiratory diseases with disease‐modifying potential. While randomised trials support its efficacy in controlling allergic rhinitis (AR) and asthma symptoms, long‐term real‐world data in children remain limited. Methods: This paediatric study ( n = 11,036) was conducted within the pre‐defined framework of the REACT study, based on protocol‐specified objectives. Children (< 18 years) with physician‐diagnosed AR, with or without pre‐existing asthma, were included. AIT‐treated patients were matched 1:1 to non‐AIT controls. Effectiveness was assessed over 9 years by comparing AR and asthma medication prescriptions, using a public database covering all reimbursable AIT products. Relative differences were calculated across the full observation period. Results: AIT‐treated children (mean age 11.4 years; 62.1% male) exhibited greater reductions in AR medication use than controls (additional 9% reduction beyond 61% in controls). In children with asthma, AIT was associated with additional reductions in asthma medication use (−21% beyond −48% in controls), severe exacerbations (−21% beyond −36%), and new oral corticosteroid prescriptions (−33% beyond −41%). Age stratification revealed more pronounced AR medication reductions in younger children (0–11 years) than in adolescents (12–17 years). Conclusion: This large‐scale, real‐world study supports the long‐term effectiveness of AIT in children with AR, with or without asthma. The findings reflect improved disease control and suggest a disease‐modifying effect of AIT. Early intervention, particularly in younger children, may help mitigate the progression of allergic disease.
- 1 October 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (11) , 1026-1040
Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage
- 1 October 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (11) , 1026-1040
Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage
- Open Access
Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities
Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs. Despite a consensus that the use of OCS should be minimized in asthma treatment strategies, many patients still routinely receive long‐term or frequent short courses of OCS. Add‐on biologics can help to improve asthma control in patients with severe asthma and evidence of type 2 inflammation; in clinical trials and real‐world studies, both short‐ and long‐term OCS‐sparing effects have been demonstrated. In this review, we discuss the benefits and burdens of OCS in patients with severe asthma from the perspective of both patients and healthcare providers and outline potential methods for reducing reliance on OCS. Given the risk of adrenal insufficiency or crisis upon cessation of OCS, we discuss the need for clear guidance and algorithms for the tapering of OCS together with the requirement for multidisciplinary patient–provider interactions as part of an effective OCS stewardship scheme.
Open AccessBurden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities
Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs. Despite a consensus that the use of OCS should be minimized in asthma treatment strategies, many patients still routinely receive long‐term or frequent short courses of OCS. Add‐on biologics can help to improve asthma control in patients with severe asthma and evidence of type 2 inflammation; in clinical trials and real‐world studies, both short‐ and long‐term OCS‐sparing effects have been demonstrated. In this review, we discuss the benefits and burdens of OCS in patients with severe asthma from the perspective of both patients and healthcare providers and outline potential methods for reducing reliance on OCS. Given the risk of adrenal insufficiency or crisis upon cessation of OCS, we discuss the need for clear guidance and algorithms for the tapering of OCS together with the requirement for multidisciplinary patient–provider interactions as part of an effective OCS stewardship scheme.
- Open Access
- 11 June 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 245, 108203
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
- 11 June 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 245, 108203
Open AccessClinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
- Open Access
- 1 April 2025
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 88 (2) , 193-215
International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.
- 1 April 2025
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 88 (2) , 193-215
Open AccessInternational Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.
- Open Access
- 5 March 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (7) , 1246-1256
The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma
IntroductionSevere asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment.MethodsThis cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment tracked in national databases from one year prior to biologic therapy as well as during two years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population.ResultsOverall, 381 patients aged 20-62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80-0.84)), driven by increases in sick-leave (aIRR 2.77 (2.58-2.98)), unemployment (aIRR 1.38 (1.30-1.46)) and disability pension (aIRR 1.85 (1.76-1.94)).After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03-1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15-2.93)) and permanent (OR 2.67 (1.16-6.16)) workforce withdrawal.Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years.ConclusionBiologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.
- 5 March 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (7) , 1246-1256
Open AccessThe impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma
IntroductionSevere asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment.MethodsThis cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment tracked in national databases from one year prior to biologic therapy as well as during two years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population.ResultsOverall, 381 patients aged 20-62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80-0.84)), driven by increases in sick-leave (aIRR 2.77 (2.58-2.98)), unemployment (aIRR 1.38 (1.30-1.46)) and disability pension (aIRR 1.85 (1.76-1.94)).After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03-1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15-2.93)) and permanent (OR 2.67 (1.16-6.16)) workforce withdrawal.Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years.ConclusionBiologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy.
Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma
Background: In patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes. Methods: We used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease. Results: We identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function. Conclusions: FeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.
Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma
Background: In patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes. Methods: We used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease. Results: We identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function. Conclusions: FeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA3649
Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial
Introduction: Mucus hypersecretion resulting from type 2 inflammatory cytokines (e.g., interleukin [IL]-13) drives intermittent airway obstruction and remodelling. Dupilumab blocks the IL-4/13 receptor, improves lung function, and reduces rates of severe exacerbations in patients with asthma, with an acceptable safety profile. The VESTIGE study (NCT04400318) assessed dupilumab impact on airway mucus plugging and volume, inflammation, and lung function. Methods: Patients (21-70 years) with uncontrolled moderate-to-severe asthma, elevated type 2 biomarkers (baseline blood eosinophil count≥300 cells/µL; fractional exhaled nitric oxide [FeNO]≥25 ppb), pre-bronchodilator percent predicted forced expiratory volume in 1 second (pre-BD ppFEV1)≤80%, and ≥1 exacerbation year prior were randomized 2:1 to add-on dupilumab 300 mg (N=72) or matched placebo (PBO, N=37) q2w for 24 weeks. We quantified occluded bronchopulmonary segments to give mucus plug scores (0–20). Voxels per mucus plug, measured by CT, gave mucus volumes. We also assessed FeNO and pre-BD ppFEV1 at Week 24. Results: The dupilumab group had reduced mucus scores (least squares mean difference [LSMD][SE] from baseline:–4.9 [0.8] points vs PBO; nominal P <0.001) and volumes (–0.11 [0.02] mL; nominal P <0.001), were 9.8 times more likely to achieve FeNO<25 ppb (P <0.001), and improved in pre-BD ppFEV1 (LSMD[SE]: 13.8 [3.1] %, nominal P <0.001). Improvements from baseline to Week 24 in pre-BD ppFEV1 correlated with lower mucus score in the dupilumab group (Pearson’s correlation coefficient: –0.61 (P <0.0001)). Conclusion: Dupilumab treatment led to reductions in airway mucus plugging, mucus volume, and inflammation, likely contributing to improved lung function.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA3649
Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial
Introduction: Mucus hypersecretion resulting from type 2 inflammatory cytokines (e.g., interleukin [IL]-13) drives intermittent airway obstruction and remodelling. Dupilumab blocks the IL-4/13 receptor, improves lung function, and reduces rates of severe exacerbations in patients with asthma, with an acceptable safety profile. The VESTIGE study (NCT04400318) assessed dupilumab impact on airway mucus plugging and volume, inflammation, and lung function. Methods: Patients (21-70 years) with uncontrolled moderate-to-severe asthma, elevated type 2 biomarkers (baseline blood eosinophil count≥300 cells/µL; fractional exhaled nitric oxide [FeNO]≥25 ppb), pre-bronchodilator percent predicted forced expiratory volume in 1 second (pre-BD ppFEV1)≤80%, and ≥1 exacerbation year prior were randomized 2:1 to add-on dupilumab 300 mg (N=72) or matched placebo (PBO, N=37) q2w for 24 weeks. We quantified occluded bronchopulmonary segments to give mucus plug scores (0–20). Voxels per mucus plug, measured by CT, gave mucus volumes. We also assessed FeNO and pre-BD ppFEV1 at Week 24. Results: The dupilumab group had reduced mucus scores (least squares mean difference [LSMD][SE] from baseline:–4.9 [0.8] points vs PBO; nominal P <0.001) and volumes (–0.11 [0.02] mL; nominal P <0.001), were 9.8 times more likely to achieve FeNO<25 ppb (P <0.001), and improved in pre-BD ppFEV1 (LSMD[SE]: 13.8 [3.1] %, nominal P <0.001). Improvements from baseline to Week 24 in pre-BD ppFEV1 correlated with lower mucus score in the dupilumab group (Pearson’s correlation coefficient: –0.61 (P <0.0001)). Conclusion: Dupilumab treatment led to reductions in airway mucus plugging, mucus volume, and inflammation, likely contributing to improved lung function.